Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma

American Journal of Ophthalmology

Volumn 131, Issue 6, 2001, Pages 729-733

  Konstas, Anastasios G P ^a   Stewart, William C ^b,c   Topouzis, Fotis ^d   Tersis, Ioannis ^a   Holmes, Keri T ^b   Stangos, Nikolaus T ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b University of South Carolina   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; OPTIC DISK CUP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONOMETRY; VISUAL ACUITY; VISUAL FIELD;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PROSPECTIVE STUDIES; QUINOXALINES; TIMOLOL;

EID: 0035013969     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)00834-0     Document Type: Article

References (16)

1. Ritch R, Shields MB, Krupin T. The glaucomas, 2nd ed. St. Louis: CV Mosby, 1995:1512.
2. Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate. Efficacy and safety. Arch Ophthalmol 1979;97:656.
3. Diamond GR, Werblin TP, Richter R, Radius R, Pollack IP, Maumenee AE. Extended clinical studies using timolol in patients with ocular hypertension and chronic open-angle glaucoma. Glaucoma 1979;1:63.
4. Merte HJ, Merkle W. Experiences in a double-blind study with different concentrations of timolol and pilocarpine. Klin Mnatsbl Augenheilkd 1980;177:443.
5. Widder W. Timolol eyedrops in ophthalmological practice. Klin Monatsbl Augenheilkd 1980;176:430.
6. Stewart WC, Day DC, Sharpe ED, Dubner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily versus timolol gel added to latanoprost. Am J Ophthalmol 1999;128:692-696.
7. Stewart WC, Leland TM, Gate EA, Stewart JA. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma 1998;7:402-407.
8. Stewart WC, Castelli WP. Systemic side effects of topical adrenegic blockers. Clin Cardiol 1996;19:691-697.
9. Stewart WC, Garrison PM. Beta-blocker induced complication and the glaucoma patient: newer treatments to help reduce systemic side effects. Arch Intern Med 1998;158:221-226.
10. Katz LJ. Brimonidine tartrate 0.2% twice daliy versus timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-26.
11. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41:S27-S37.
12. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105:1960-1967.
13. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41:S19-S26.
14. Konstas AGP, Mantziris DA, Stewart DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:182-185.
15. Konstas AGP, Mantziris DA, Gate EA, Stewart WC. Effect of timolol on the diurnal intraocular in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:975-979.
16. Mundorf TK, Gate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther 1998;14:129-135.